Vor Biopharma
71 hedge funds and large institutions have $188M invested in Vor Biopharma in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 11 closing their positions.
600% more call options, than puts
Call options by funds: $105K | Put options by funds: $15K
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
20% more funds holding
Funds holding: 59 → 71 (+12)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0.02% less ownership
Funds ownership: 4.56% → 4.54% (-0.02%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
42% less capital invested
Capital invested by funds: $326M → $188M (-$138M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.75M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.64M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.86M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.29M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$608K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$9.46M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.75M |
| 3 |
Millennium Management
New York
|
-$1.57M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.19M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$570K |
VOR Hedge Fund Activity: Q2 2023 in Review
71 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2023, worth a combined $188M — down 42% from $326M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VOR positions and 11 closed out — a net gain of 12 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $7.75M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $9.46M sold.
- 71 institutional investors held Vor Biopharma (VOR) as of Q2 2023, up from 59 in Q1 2023.
- Funds reported $188M of Vor Biopharma stock for Q2 2023, down 42% quarter-over-quarter.
- 23 funds opened new Vor Biopharma positions in Q2 2023 and 11 closed out, a net change of +12 holders.
- The largest Vor Biopharma buyer in Q2 2023 was BlackRock, an estimated $7.75M added.
- The largest Vor Biopharma seller in Q2 2023 was Janus Henderson Group, an estimated $9.46M sold.
Based on aggregated 13F filings for Q2 2023.